Is R2* a new MRI biomarker for the progression of Parkinson's disease? A longitudinal follow-up. - Wikidata - wikimedia - TriplyDB

Is R2* a new MRI biomarker for the progression of Parkinson's disease? A longitudinal follow-up.

Is R2* a new MRI biomarker for the progression of Parkinson's disease? A longitudinal follow-up.

http://www.wikidata.org/entity/Q30457611

about

Appraising the Role of Iron in Brain Aging and Cognition: Promises and Limitations of MRI Methods Magnetic resonance imaging (MRI) to study striatal iron accumulation in a rat model of Parkinson's disease Global, Yet Incomplete Overview of Cohort Studies in Parkinson's disease.The presence and role of iron in mild traumatic brain injury: an imaging perspective.Quantitative susceptibility mapping (QSM): Decoding MRI data for a tissue magnetic biomarker.Recent imaging advances in neurology.Longitudinal changes in free-water within the substantia nigra of Parkinson's disease Excessive early-life dietary exposure: a potential source of elevated brain iron and a risk factor for Parkinson's disease.Post translational changes to α-synuclein control iron and dopamine trafficking; a concept for neuron vulnerability in Parkinson's disease.Brain Magnetic Resonance Imaging (MRI) as a Potential Biomarker for Parkinson's Disease (PD).Iron accumulation confers neurotoxicity to a vulnerable population of nigral neurons: implications for Parkinson's disease.Imaging biomarkers in Parkinson's disease and Parkinsonian syndromes: current and emerging concepts.Striatal iron content predicts its shrinkage and changes in verbal working memory after two years in healthy adults.A multicontrast approach for comprehensive imaging of substantia nigra.Potential of Diffusion Tensor Imaging and Relaxometry for the Detection of Specific Pathological Alterations in Parkinson's Disease (PD)Magnetic Resonance Imaging Features of the Nigrostriatal System: Biomarkers of Parkinson's Disease Stages?Quantitative Susceptibility Mapping in Parkinson's Disease.The role of high-field magnetic resonance imaging in parkinsonian disorders: Pushing the boundaries forward.Region-Specific Iron Measured by MRI as a Biomarker for Parkinson's Disease.Putaminal Diffusivity Correlates With Disease Progression in Parkinson's Disease: Prospective 6-Year Study Accumulation of iron in the putamen predicts its shrinkage in healthy older adults: A multi-occasion longitudinal study Increased R2* in the Caudate Nucleus of Asymptomatic Welders.Lateral Asymmetry and Spatial Difference of Iron Deposition in the Substantia Nigra of Patients with Parkinson Disease Measured with Quantitative Susceptibility Mapping Neuromelanin Imaging and Dopaminergic Loss in Parkinson's Disease Meta-analysis of brain iron levels of Parkinson's disease patients determined by postmortem and MRI measurements.Biomarkers in Parkinson's disease: Advances and strategies.Quantitative susceptibility mapping of the midbrain in Parkinson's disease The iron regulatory capability of the major protein participants in prevalent neurodegenerative disorders.Recent developments in biomarkers in Parkinson disease Imaging synucleinopathies.Longitudinal changes of cortical microstructure in Parkinson's disease assessed with T1 relaxometry Iron quantification with susceptibility.Parkinson's disease-related increase of T2*-weighted hypointensity in substantia nigra pars compacta.Association of neurobehavioral performance with R2* in the caudate nucleus of asymptomatic welders.Clinical quantitative susceptibility mapping (QSM): Biometal imaging and its emerging roles in patient care.Multimodal MRI assessment of nigro-striatal pathway in multiple system atrophy and Parkinson disease.T2* Relaxometry in Patients with Parkinson's Disease : Use of an Automated Atlas-based Approach.Magnetic resonance imaging and tensor-based morphometry in the MPTP non-human primate model of Parkinson's disease.Nigral iron elevation is an invariable feature of Parkinson's disease and is a sufficient cause of neurodegeneration.Higher Striatal Iron Concentration is Linked to Frontostriatal Underactivation and Poorer Memory in Normal Aging.

P2860

Q26779470-B56F108A-0CC4-4778-A42B-96DDC1F66846 Q27325407-406E6782-6F45-4B4F-9CB2-AC2E1760E8FF Q30491906-10C5934F-C64F-408F-A7A5-AF981AFB0EDC Q30705365-9C9A8672-941C-4A5B-90E5-DFAE0F6D640D Q30837513-30B0A404-C567-4493-9390-BF9A12F14819 Q30916063-BE9D0F0C-E2A1-4DF9-8C79-9BC78E44D516 Q30952963-8609C914-BD7D-4083-B9EA-D5C5BF7A5321 Q33767295-DA168FCF-4559-44DE-8D7B-FE2F4385920C Q33776138-5CA7F6ED-D8A0-4E34-BCF3-90FD52CAC3A8 Q33831798-4867FE38-56F5-4631-925B-E6AD7855BD2E Q33965221-869D29A8-2935-4FB2-AF5A-301EB36127B1 Q34554452-F7CFE875-5641-40C1-B8FB-1C33B14BE9B4 Q35547874-8D2A55E6-F538-46C0-B841-497A4AC61982 Q35555926-B6F4E15B-33CD-41EB-AF37-B344BC69A5C8 Q35880556-75D88AA6-1EAD-4D64-A76D-214659F7F692 Q35976522-01B8ADFB-B60C-4407-8082-594A611C29F1 Q36123740-EDE12AEF-7562-4282-A449-7E66686A6E40 Q36332532-683D8E31-5B46-4DE6-921F-4FD9A6B01BAA Q36374541-7F71A923-D244-43C7-B21E-F8C628A4353C Q36580852-0A718E07-50D2-41E2-927F-47D7FBE4A721 Q36604603-51AEFB4E-6CB6-45E9-BFA0-0E881FF47FF1 Q36871031-4AB3CAE2-DE92-43CE-BAD1-70AC3C746FC5 Q36902028-DB4F6AC3-F9C7-42D7-A871-2F4E0A8CDAD5 Q37192855-91917FA5-2A33-46AA-89EE-826F26D85470 Q37402514-6D9ECF0E-0B57-4EE2-8645-C18CB80AC7A1 Q37431507-4149D123-E662-49EE-B054-38836B44C67D Q37650486-DC1C418A-9F67-426D-8585-7A03C4E74D0C Q37725605-D681B84E-9A94-4465-8996-CF85538A2260 Q38119095-E7466E30-C336-494F-9D20-E4C31149E4EE Q38734660-43FB67DC-A69F-4437-9B28-D53C16D52C91 Q38766599-0CCC9CEF-A8C6-4B31-BBAF-522C852746E2 Q38818883-5E9508D8-C941-4F11-AACF-2A248AC5868B Q39075112-641055B5-EA5E-4CE3-A384-0321FB931D4F Q39166857-4FCB7399-38EF-436E-A2F0-5526EF1EC02D Q39179797-AD1E96AF-A6AE-4856-9B0F-0995C2E5BCE8 Q40202363-E7C0AB66-4C1F-452D-8DB0-23A8D5F16374 Q40384244-9707B6E6-4240-4B9A-AD75-B6DFFA7F5FE9 Q41105821-39ACB8AF-5C66-449B-880D-655DD134B29C Q41825693-CF4F9CB6-E730-4478-B90E-63AC7BA694B0 Q47768724-94EDB3FB-C332-4BF5-873E-D8A5E792D575

P2860

Is R2* a new MRI biomarker for the progression of Parkinson's disease? A longitudinal follow-up.

http://www.wikidata.org/entity/Q30457611

description

2013 nî lūn-bûn

@nan

2013 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի մարտին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Is R2* a new MRI biomarker for ...... ase? A longitudinal follow-up.

@ast

Is R2* a new MRI biomarker for ...... ase? A longitudinal follow-up.

@en

type

label

Is R2* a new MRI biomarker for ...... ase? A longitudinal follow-up.

@ast

Is R2* a new MRI biomarker for ...... ase? A longitudinal follow-up.

@en

prefLabel

Is R2* a new MRI biomarker for ...... ase? A longitudinal follow-up.

@ast

Is R2* a new MRI biomarker for ...... ase? A longitudinal follow-up.

@en

P1433

Q30457611-473E87B2-8DAC-4D32-8FBD-3B50013A1A71

P1476

Q30457611-EEEB7868-62A5-4601-9657-2A4F1CDDDCB9

P2093

Q30457611-05F6D6E8-4D5F-4536-90FC-7B307C9093A9

Q30457611-10CFC83E-A09F-44B0-A732-2C9AFC896F67

Q30457611-5C2CF573-F96A-46D0-84BE-B2628D609DB5

Q30457611-B72FF562-D382-4D28-9317-46EAE013454F

Q30457611-DC445592-9A73-4B5F-A80A-84487C83AB78

Q30457611-E6ABD38E-17AD-4935-9132-316745F06EF8

P2860

Q30457611-025408A6-B97A-47BB-866D-D299E790C7F2

Q30457611-0543802C-1A3F-462A-9E6A-12B4A7E0FA51

Q30457611-055FEBDA-4AE7-4AC8-86E2-18C7F4D43CD3

Q30457611-0616E31A-5DB3-4352-88F4-86E14361FAD3

Q30457611-10639031-EEE3-4E6C-A577-AE7405A13866

Q30457611-1967C952-7960-470D-8A68-E055CD59AC41

Q30457611-2047A28D-0F92-44B7-BB76-2F57203B3C6F

Q30457611-27DBE91E-7205-4209-8761-FC4B0AAFE174

Q30457611-2911ACB0-209B-40C0-BF7B-51D0F8EEC124

Q30457611-47E4C308-8E9F-4E18-8499-61AE4DE67BF9

P304

Q30457611-33EF772C-0321-40CF-BDA5-5A465CCFEEC7

P31

Q30457611-C0E8B08F-A9A7-4187-93E5-B6AEB7056CF1

P356

Q30457611-B34DC5EC-4B54-4D7E-9D22-62AEA9A26B8C

P407

Q30457611-CB1BCE79-D576-4BE8-958B-0753104880E6

P433

Q30457611-F7527D25-4A5E-4AB6-A76E-68FBF74C7E1B

P478

Q30457611-F3174C89-B620-48D9-BBB8-B53F20F8527A

P577

Q30457611-A6E5F3F7-A30C-40D0-BA74-393889F0C90E

P5875

Q30457611-A5DD4F53-ADB8-4D4D-8820-0A593BB6C884

P698

Q30457611-21ABD894-9854-405B-B6D6-F207B3FFC237

P921

Q30457611-0C3BCCAB-7865-4AD0-BBA9-EDF204C4BA7C

Q30457611-6BB096E8-B24B-4E64-9AE2-2CD7E292FC8F

P932

Q30457611-A6B26993-9AF9-47A2-B398-0B20F9CB86E6

P356

JOURNAL.PONE.0057904

P1433

P1476

Is R2* a new MRI biomarker for ...... ase? A longitudinal follow-up.

@en

P2093

Beatrice Claise

http://www.w3.org/2001/XMLSchema#string

Franck Durif

http://www.w3.org/2001/XMLSchema#string

Isabelle Rieu

http://www.w3.org/2001/XMLSchema#string

Jean Marie Bonny

http://www.w3.org/2001/XMLSchema#string

Lemlih Ouchchane

http://www.w3.org/2001/XMLSchema#string

Miguel Ulla

http://www.w3.org/2001/XMLSchema#string

P2860

Iron, brain ageing and neurodegenerative disorders

Neuroinflammation in Parkinson's disease: a target for neuroprotection?

Proposed dose equivalence for rapid switch between dopamine receptor agonists in Parkinson's disease: a review of the literature.

Potential sources of increased iron in the substantia nigra of parkinsonian patients.

Alterations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia.

Estimation of brain iron concentration in vivo using a linear relationship between regional iron and apparent transverse relaxation rate of the tissue water at 4.7T.

The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease

Theory of NMR signal behavior in magnetically inhomogeneous tissues: the static dephasing regime.

Using high-resolution MR imaging at 7T to evaluate the anatomy of the midbrain dopaminergic system.

Combined R2* and diffusion tensor imaging changes in the substantia nigra in Parkinson's disease.

P304

e57904

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0057904

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P577

2013-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

235883311

http://www.w3.org/2001/XMLSchema#string

P698

23469252

http://www.w3.org/2001/XMLSchema#string

P921

Parkinson's disease

P932

3585727

http://www.w3.org/2001/XMLSchema#string